Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application

Main Article Content

James Del Rosso
Scott Guenthner
Chih-ho Hong
John E Jett
Philip M Brown
David S Rubenstein
Stephen C Piscitelli
Stephen C Piscitelli

Keywords

tapinarof, psoriasis, efficacy

Abstract

N/A

References

1. Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information. 2022. https://www.vtama.com/docs/DMVT_VTAMA_PI.pdf. Accessed July 2022.

2. Lebwohl MG, et al. N Engl J Med. 2021;385:2219–2229.

3. Strober B, et al. J Am Acad Dermatol. 2022. https://doi.org/10.1016/j.jaad.2022.06.1171.

4. Jett JE, et al. Am J Clin Dermatol. 2022;23(1):83–91.

5. Peppers J, et al. J Am Acad Dermatol. 2019;80(1):89–98

Most read articles by the same author(s)

1 2 3 4 5 6 > >>